Conditions: Psoriasis
Keywords: Moderate to severe psoriasis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 36
Healthy volunteers: no

Brief summary:
This study aims to see if patient quality of life can be approved after treatment with an injectable medication called ustekinumab for the treatment of generalized psoriasis. The investigators hypothesize that the investigators will see improvement in quality of life.

Detailed description:
The primary objective of this study is to demonstrate improvement in psoriasis patient quality of life after 36 weeks with ustekinumab through the use of validated dermatologic and non-dermatologic psychometric instruments.

Arms:
arm 1: None

Interventions: intervention 1: Ustekinumab
Intervention descriptions: intervention 1: Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.

Protocol document: